Recommendations for treating HER2-positive metastatic breast cancer with newer HER2-targeted treatment approaches and considerations regarding their adoption into clinical practice.
EP. 2: Newer Targeted Therapies for HER2+ Metastatic Breast CancerJune 15th 2021
Ian E. Krop, MD, PhD, of Dana-Faber Cancer Institute, highlights more recent targeted therapy approvals for HER2-positive metastatic breast cancer and describes how each therapy is designed to work.
EP. 6: COVID-19 and the Use of HER2-Targeted Therapy for MBCJune 29th 2021
The impact of the COVID-19 pandemic on the utilization of newer targeted therapies for HER2-positive metastatic breast cancer and considerations regarding their adoption into clinical practice based on the availability of vaccines.
EP. 7: Frontline Treatment Standards for HER2+ mBCJuly 21st 2021
Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.
EP. 13: Value-Based Decision-Making in Metastatic Breast CancerSeptember 16th 2021
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.